The effect of evinacumab on the clinical outcomes of dyslipidemia: A systematic review of randomized controlled trials.
BACKGROUND Residual atherosclerotic cardiovascular disease risk remains substantial despite optimal conventional lipid-lowering therapy, particularly in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C). Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3, represents a...